Related Experiment Video

Updated: Feb 20, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer

Nikolaos Dervisis1, Shawna Klahn2

  • 1Virginia Maryland College of Veterinary Medicine, 245 Duck Pond Dr., Blacksburg, VA 24061, USA. dervisis@vt.edu.

Veterinary Sciences
|October 24, 2017
PubMed

Insights

Targeted therapies, like kinase inhibitors, are revolutionizing cancer treatment by targeting specific pathways. Comparative oncology offers a path to overcome challenges in developing and applying these advanced cancer drugs.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Conventional chemotherapy's limitations in cancer management.
  • The rise of targeted therapies and their importance in medicine.
  • Tyrosine kinases' role in various diseases, including cancer.

Purpose of the Study:

  • To highlight the significance of tyrosine kinases in disease.
  • To discuss the challenges in kinase inhibitor drug development.
  • To explore the potential of comparative oncology in advancing kinase inhibitor therapy.

Main Methods:

  • Review of current literature on targeted cancer therapies.
  • Analysis of the drug development pipeline for kinase inhibitors.
  • Exploration of comparative oncology models for therapeutic research.

Main Results:

  • Tyrosine kinase inhibitors represent a major area of pharmaceutical development.
  • Significant hurdles exist between discovery and approval of kinase inhibitors.
  • Comparative oncology presents a novel approach to address these hurdles.

Conclusions:

  • Kinase inhibitors show promise for cancer treatment and diagnosis.
  • Unanswered questions remain regarding kinase inhibitor application in cancer care.
  • Comparative oncology can help overcome limitations in kinase inhibitor therapy advancement.
Keywords:
cancercatchemotherapycomparativedoghumantyrosine kinase inhibitors

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
578
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K